Company Overview of Affimed N.V.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company’s product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor v...
Im Neuenheimer Feld 582
Founded in 2000
Key Executives for Affimed N.V.
Chief Executive Officer and Member of Management Board
Total Annual Compensation: $297.0K
Chief Financial Officer and Member of Management Board
Total Annual Compensation: $190.0K
Chief Medical Officer and Member of Management Board
Total Annual Compensation: $352.0K
Compensation as of Fiscal Year 2014.
Affimed N.V. Key Developments
Affimed N.V.(NasdaqGM:AFMD) added to Russell 2000 Index
Jun 30 15
Affimed N.V. will be added to Russell 2000 Index
Affimed N.V.(NasdaqGM:AFMD) added to Russell 3000 Index
Jun 30 15
Affimed N.V. will be added to the Russell 3000 Index.
Affimed N.V. Announces Opening of US Operations; Announces Executive Appointment for New Operations
Jun 23 15
Affimed N.V. announced that it has established operations in the United States.
The company also announced that Caroline Stewart and Dr. Oscar Kashala have joined the company as Head of Investor Relations & Communication and Vice President, Medical US respectively. Caroline brings nearly twenty years of combined experience on Wall Street and in the pharmaceutical industry to the company. Oscar is a biopharmaceutical executive with expertise in early to late-stage development of oncology and infectious diseases products. He held positions of increasing responsibility at Cambridge Biotech/Aquila Biopharmaceuticals, Lexigen Pharmaceuticals, Millennium Pharmaceuticals, and EMD Serono, where he led the efforts to develop immunotherapy for solid tumors and hematologic cancers.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 2, 2014
Most Searched Private Companies
Sponsored Financial Commentaries